CO,
I believe you're numbers are possible, but not for some time. That sort of valuation will require our vaccines to be accepted in many solid cancers, and note I said vaccines. DCVax-Direct needs to be far enough advanced that it's approval is deemed to be just a matter of time to get adequate patients enrolled for a sufficient period of time.
Frankly if we have approval of both vaccines in multiple cancers I don't believe $100 billion would be considered, in fact by then I believe our market cap would be substantially greater than that. I'd say that 4 to 6 years from now enough will be known to elicit a $100 billion offer if all is going well by then. I suspect we'll have a BP partner well before then, but such a partnership doesn't preclude a buyout offer either from that partner, or anyone else who wants to compete for the company.
No telling what a bidding war could bring, but we shouldn't be in too great a rush to encourage this to happen. No company in their right mind will pay more than double the current market cap.
Gary
News 
Market Data 
Discover 
